{"id":65567,"date":"2025-03-12T12:02:17","date_gmt":"2025-03-12T12:02:17","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/03\/12\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/"},"modified":"2025-03-12T12:02:17","modified_gmt":"2025-03-12T12:02:17","slug":"acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/","title":{"rendered":"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting"},"content":{"rendered":"<div>\n<p><em>Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug<\/em><\/p>\n<p align=\"justify\">NEWTON, Mass., March  12, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rcfwXB8Vdt5c8GJdPdmjsTQ9AJpjyLYHugOnFlNVkyqrzAQa6qYqd6wMysJ5jgzK2J6_l02tIHnHIxmo-hlr6Fy0uHT9ar9SvkeJml6UHfE=\" rel=\"nofollow\" target=\"_blank\" title=\"Acumen Pharmaceuticals, Inc.\">Acumen Pharmaceuticals, Inc.<\/a> (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD),\u00a0today announced upcoming scientific presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases and Related Neurological Disorders (AD\/PD) in Vienna, Austria from April 1-5, 2025, and the American Academy of Neurology (AAN) Annual Meeting in San Diego, Calif., from April 5-9, 2025.<\/p>\n<p align=\"justify\">Oral presentations will focus on implementation of a validated research-use plasma pTau217 assay in the clinical trial participant screening process. Poster presentations will focus on methods of interrogating the binding of A\u03b2Os to a model of human neurons; methods to more accurately assess the A\u03b2O selectivity of nonclinical assays and sabirnetug; and early effects of sabirnetug on synaptic biomarkers in AD. Together, these presentations support the comprehensive development program for sabirnetug, which Acumen is advancing as a potential next-generation antibody treatment for early symptomatic AD.<\/p>\n<p align=\"justify\">AD\/PD presentation details are as follows:<\/p>\n<p align=\"justify\"><u>Oral Presentation<\/u><\/p>\n<p><strong>ALTITUDE-AD: Use of Plasma pTau217 Screening in An Ongoing Phase 2 Study of Sabirnetug for Early Symptomatic Alzheimer&#8217;s Disease (2813)<\/strong><\/p>\n<ul type=\"circle\">\n<li><strong>Date\/Time:<\/strong> April 1, 2025, 2:30-2:45 p.m. CEST<\/li>\n<li><strong>Location:<\/strong> Austria Center Vienna, Hall A<\/li>\n<li><strong>Presenting Author: <\/strong>Eric Siemers<\/li>\n<\/ul>\n<p><u>Poster Presentations<\/u><\/p>\n<p><strong>Protocol for the Preparation of Stable Monomeric Amyloid Beta (1522)<\/strong><\/p>\n<ul type=\"circle\">\n<li><strong>Dates:<\/strong> April 2-3, 2025<\/li>\n<li><strong>Location:<\/strong> Austria Center Vienna, Exhibition Hall<\/li>\n<li><strong>Presenting Author: <\/strong>Erika Cline<\/li>\n<\/ul>\n<p><strong>Utility of Human i<\/strong><strong>PSC-<\/strong><strong>Derived Neuronal Model for Evaluating Synaptic Binding of Amyloid \u0392eta Oligomers (1393)<\/strong><\/p>\n<ul type=\"circle\">\n<li><strong>Dates:<\/strong> April 2-3, 2025<\/li>\n<li><strong>Location:<\/strong> Austria Center Vienna, Exhibition Hall<\/li>\n<li><strong>Presenting Author: <\/strong>Elizabeth Johnson<\/li>\n<\/ul>\n<p>AAN presentation details are as follows:<\/p>\n<p><u>Oral Presentation<\/u>\u00a0<\/p>\n<p><strong>ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer&#8217;s Disease<\/strong>\u00a0<strong>(3870)<\/strong><\/p>\n<ul type=\"circle\">\n<li><strong>Date\/Time:<\/strong>\u00a0April 7, 2025, 2:24 p.m. PT<\/li>\n<li><strong>Location:<\/strong>\u00a0 San Diego Convention Center, 25C<\/li>\n<li><strong>Presenting Author:\u00a0<\/strong>Todd Feaster<\/li>\n<\/ul>\n<p><u>Poster Presentation<\/u>\u00a0<\/p>\n<p><strong>INTERCEPT-AD Biomarker Results: Early effect of sabirnetug treatment on synaptic biomarkers in Alzheimer&#8217;s disease<\/strong>\u00a0<strong>(3984)<\/strong><\/p>\n<ul type=\"circle\">\n<li><strong>Date\/Time:<\/strong>\u00a0April 9, 2025, 11:45 a.m. \u2013 12:45 p.m. PT<\/li>\n<li><strong>Location:<\/strong>\u00a0San Diego Convention Center, Poster Hall<\/li>\n<li><strong>Presenting Author:\u00a0<\/strong>Elizabeth Johnson<\/li>\n<\/ul>\n<p align=\"justify\"><strong>About Sabirnetug (ACU193)<\/strong><\/p>\n<p align=\"justify\">Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (A\u03b2Os), which are a highly toxic and pathogenic form of A\u03b2, relative to A\u03b2 monomers and amyloid plaques. Soluble A\u03b2Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A\u03b2Os, sabirnetug aims to address the hypothesis that soluble A\u03b2Os are an early and persistent underlying cause of the neurodegenerative process in Alzheimer\u2019s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.<\/p>\n<p align=\"justify\"><strong>About ALTITUDE-AD (Phase 2)<\/strong><\/p>\n<p align=\"justify\">Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer&#8217;s disease. The study will enroll approximately 540 individuals with early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia due to AD). The global study is currently ongoing at multiple investigative sites located in the United States, Canada, UK, and the European Union. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.<\/p>\n<p align=\"justify\"><strong>About Acumen Pharmaceuticals, Inc.<\/strong><\/p>\n<p align=\"justify\">Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A\u03b2Os) for the treatment of Alzheimer\u2019s disease (AD). Acumen\u2019s scientific founders pioneered research on A\u03b2Os, which a growing body of evidence indicates are early and persistent triggers of Alzheimer\u2019s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble A\u03b2Os, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer\u2019s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=du5HX8XCN8e3ueTobWzUs0ffQG5PFyxLiFywq8Qq6M1WvNyfEZWqQMHCgcVCmvIEXDOjwv-FRsg7fI9qWahL_xPsxMuTbWPvp-4DkSeSZ2g=\" rel=\"nofollow\" target=\"_blank\" title=\"www.acumenpharm.com\">www.acumenpharm.com<\/a>.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen\u2019s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as \u201cpotential,\u201d \u201cwill\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential and potential clinical efficacy of Acumen\u2019s product candidate, sabirnetug (ACU193). These statements are based upon the current beliefs and expectations of Acumen\u2019s management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen\u2019s programs are described in additional detail in Acumen\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including in Acumen\u2019s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.<\/p>\n<p><strong>Investors: <\/strong><br \/>Alex Braun<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MjD2RLzddScqPtojq5jiUjGgJPufkYXBmELEJgDF1Wkby5g6RnRuMi--dQw2A0j2OJBLktbuVeV1JdgRDOWG7vd2v-BCQlR_4lQkZOP4JAo=\" rel=\"nofollow\" target=\"_blank\" title=\"abraun@acumenpharm.com\">abraun@acumenpharm.com<\/a><\/p>\n<p><strong>Media:<\/strong><br \/>Jon Yu<br \/>ICR Healthcare <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rcfwXB8Vdt5c8GJdPdmjsUfJKTaOSM_l4YwYg6THlZZ6Qyyq3xubOeAA2zG9pJ2eS0N_5lt3_5tNUR3Lmc11-MfmOLbhikojqWHC66PzyjkdhHHohq-aGSzqzR652Ncr\" rel=\"nofollow\" target=\"_blank\" title=\"AcumenPR@icrhealthcare.com\">AcumenPR@icrhealthcare.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzExMGM2YTEtNGVmNi00MTMwLWFjN2EtYTAwZjNjNjE0Zjk0LTEyMjIyMzUtMjAyNS0wMy0xMi1lbg==\/tiny\/Acumen-Pharmaceuticals-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug NEWTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) &#8212; Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (A\u03b2Os) for [&#8230;]\n","protected":false},"author":1,"featured_media":65568,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-65567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting\" \/>\n<meta property=\"og:description\" content=\"Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Pha\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-12T12:02:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/03\/Acumen-Pharmaceuticals-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting\",\"datePublished\":\"2025-03-12T12:02:17+00:00\",\"dateModified\":\"2025-03-12T12:02:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/\"},\"wordCount\":1023,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/\",\"name\":\"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-03-12T12:02:17+00:00\",\"dateModified\":\"2025-03-12T12:02:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting","og_description":"Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Pha","og_url":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-03-12T12:02:17+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/03\/Acumen-Pharmaceuticals-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting","datePublished":"2025-03-12T12:02:17+00:00","dateModified":"2025-03-12T12:02:17+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/"},"wordCount":1023,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/","url":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/","name":"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-03-12T12:02:17+00:00","dateModified":"2025-03-12T12:02:17+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/acumen-pharmaceuticals-to-present-during-international-conference-on-alzheimers-and-parkinsons-diseases-2025-and-american-academy-of-neurology-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Acumen Pharmaceuticals to Present During International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases 2025 and American Academy of Neurology Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/65567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=65567"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/65567\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/65568"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=65567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=65567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=65567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}